Synthetic lethality and the treatment of cancer
AssigneePacylex Pharmaceuticals Inc.
InventorsLuc G. Berthiaume, Erwan Beauchamp, Conganige Maneka Anne Perinpanayagam, Chuiyee Yap
Life of this patent
Estimating the term…
Abstract
Described herein are compounds, compositions and methods for treatment of cancer. Also described are methods and uses for identifying subject with cancer that are suitable for treatment with the compounds, composition and methods are described herein. In one aspect of the present invention, there is provided a method of treating a subject having a cancer deficient in NMT2, comprising: administering to said subject an NMT inhibitor.
Claims68
A method of treating a subject having a cancer deficient in NMT2, comprising:
- administering to said subject an NMT inhibitor.
A method of treating a subject having cancer, comprising:
- a. measuring a sample from said subject to determine whether said sample is deficient in NMT2;
- and
- b. administering an inhibitor of NMT to said subject when said sample is deficient in NMT2.
A kit for treating cancer in of treating a subject having a cancer deficient in NMT2, comprising:
- an NMT inhibitor;
- and instructions for the use thereof.
Use of an inhibitor NMT for treating a subject having a cancer deficient in NMT2.
Use of an inhibitor NMT for the preparation of a medicament for treating a subject having a cancer deficient in NMT2.
Use of NMT2 as a marker for one or more of diagnosis, prognosis, classifying, or monitoring of cancer in a subject.
Use of protein myristoylation as a marker for one or more of diagnosis, prognosis, classifying or monitoring cancer in a subject.
Use of protein acylation as a marker for one or more of diagnosis, prognosis, classifying or monitoring cancer in a subject.
Dependencies are inferred from the claim text.